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ABSTRACT
Introduction: Daptomycin, a rapid
concentration-dependent bactericidal
antibiotic, is approved at a dose of 4 mg/
kg/day for the treatment of complicated skin
and soft tissue infections (cSSTI) and at a dose of
6 mg/kg/day for the treatment of Staphylococcus
aureus right-sided infective endocarditis (RIE)
and bacteremia associated with cSSTI and RIE.
Studies have reported the successful use of
high-dose daptomycin ([6 mg/kg/day) in
patients with difficult-to-treat infections. The
present analysis evaluated the effectiveness and
safety of high doses ([6 mg/kg/day) of
daptomycin for the treatment of different
Gram-positive infections.
Methods: European Cubicin Outcomes
Registry and Experience (EU-CORE) is a
non-interventional, multicenter, retrospective,
patient registry designed to collect real-world
data from patients treated with daptomycin
between 2006 and 2012. Clinical outcomes
were assessed at the end of daptomycin
treatment for three dose groups: B6,[6 to\8,
and C8 mg/kg/day. Safety was assessed for up to
30 days post-daptomycin treatment.
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contains supplementary material, which is available to
authorized users.
R. A. Seaton
Queen Elizabeth University Hospital, Glasgow, UK
F. Menichetti
Azienda Ospedaliera Universitaria Pisana-Ospedale
Cisanello-U.O. Malattie Infettive, Pisa, Italy
G. Dalekos
Departments of Medicine and Research Laboratory
of Internal Medicine, School of Medicine, University
of Thessaly, Larissa, Greece
A. Beiras-Fernandez
Klinik fu¨r Herzchirurgie, Universita¨tsklinik
Großhadern, Mu¨nchen, Germany
A. Beiras-Fernandez
Department of Cardiothoracic Surgery, University of
Frankfurt, Frankfurt, Germany
F. Nacinovich
Instituto Cardiovascular de Buenos Aires, Ciudad de
Buenos Aires, Argentina
R. Pathan
Novartis Healthcare Pvt. Ltd., Hyderabad, India
K. Hamed (&)
Novartis Pharmaceuticals Corporation,
East Hanover, NJ, USA
e-mail: kamal.hamed@novartis.com
Adv Ther (2015) 32:1192–1205
DOI 10.1007/s12325-015-0267-4
Results: Of the 6075 patients enrolled in
EU-CORE, 4892 patients received daptomycin
doses B6 mg/kg/day, while 1097 patients
received high doses ([6 mg/kg/day). The
primary infections with the largest proportion
of patients treated with a high dose
([6 mg/kg/day) were osteomyelitis (37.1%),
foreign body/prosthetic infection (31.6%), and
endocarditis (27.6%). S. aureus was identified in
42.9% of patients with positive cultures treated
with either B6 or [6 mg/kg/day. The overall
clinical success rate was 82.0% (899/1097) with
high doses ([6 mg/kg/day) and 80.3%
(3928/4890) with doses B6 mg/kg/day.
Numerically higher clinical success rate was
observed for endocarditis and foreign
body/prosthetic infection, as well as for
coagulase-negative staphylococcal and
enterococcal infections, with high-dose
daptomycin treatment. There were no new
or unexpected safety findings at doses
[6 mg/kg/day.
Conclusion: These results suggested that
daptomycin at doses [6 mg/kg/day was
effective and well tolerated. High-dose
daptomycin is a potential therapeutic option
in patients with difficult-to-treat Gram-positive
infections.
Funding: This study was funded by Novartis
Pharma AG.
Keywords: Clinical response; Daptomycin;
EU-CORE; Gram-positive infections; High
dose; Infectious diseases; Safety
INTRODUCTION
Daptomycin is a cyclic lipopeptide antibiotic
that is approved at a dose of 4 mg/kg/day for the
treatment of complicated skin and soft tissue
infections (cSSTI) and at a dose of 6 mg/kg/day
for the treatment of Staphylococcus aureus
right-sided infective endocarditis (RIE) and
bacteremia associated with cSSTI and RIE [1].
It has a rapid, concentration-dependent
bactericidal activity [2]. Daptomycin exhibits a
linear pharmacokinetic profile, which is
concentration proportional for doses up to
12 mg/kg/day [2–4]. As a result of its
concentration-dependent bactericidal activity,
higher doses ([6 mg/kg/day) have often been
considered for difficult-to-treat infections [5].
Daptomycin is a recognized alternative to
vancomycin for the treatment of serious
infections [6]. Optimum dosing of daptomycin
for serious/deep-seated infection is not yet
defined. Based on its concentration-dependent
activity, higherdoses of daptomycinmay lead toa
more rapid bacterial clearance and reduce
resistance emergence [5, 7]. In infections where
there is a difficulty in achieving adequate local
antibiotic concentrationat the infectionsite, or in
patients with sepsis and high volumes of
distribution, high-dose daptomycin may also be
advantageous [4, 8]. Additionally, the intrinsic
lower susceptibility of enterococci to daptomycin
suggests that high doses of daptomycin may be
necessary to achieve good results [9].
Several national and international treatment
guidelines include high-dose daptomycin
(8–10 mg/kg/day) as a therapeutic option for
difficult-to-treat infections [6, 10–12]. The
Infectious Diseases Society of America
guidelines for the treatment of
methicillin-resistant S. aureus (MRSA)
recommend consideration of high-dose
(10 mg/kg/day) daptomycin in patients with
persistent MRSA bacteremia associated with
vancomycin failure and possible endocarditis
[6]. Also, the Spanish Society of Infectious
Diseases and Clinical Microbiology has
recently addressed the impact of an
appropriate antimicrobial treatment (empirical
and directed) and its relevance in the
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management of S. aureus infections, and the
role of high-dose daptomycin in these scenarios
[11].
Although only a limited number of clinical
trials have evaluated the safety of high-dose
daptomycin [5, 13, 14], several observational
studies have reported the successful use of
high-dose daptomycin ([6 mg/kg/day) in
patients with difficult-to-treat infections [7–9,
15–18]. To date, there are no randomized
controlled studies that have evaluated the
efficacy and safety of high-dose daptomycin.
The objective of this analysis from the European
Cubicin Outcomes Registry and Experience
(EU-CORE) study was to evaluate the
effectiveness and safety of daptomycin for the
treatment of Gram-positive infections in a
real-world setting with high doses
([6 mg/kg/day) versus current licensed doses
(4 or 6 mg/kg/day).
METHODS
Study Design and Data Collection
This was a non-interventional, multicenter,
retrospective, patient registry designed to
collect real-world outcome data on patients
who had received at least one dose of
daptomycin for the treatment of a serious
Gram-positive bacterial infection. This analysis
includes all patients enrolled in the EU-CORE
study who received any dose of daptomycin
between 2006 and 2012: B6 mg/kg/day, [6 to
\8 mg/kg/day, or C8 mg/kg/day.
Detailed EU-CORE methodology has been
described elsewhere [19]. Patients who had
received at least one dose of daptomycin, had
a minimum of 30 days post-treatment follow-up
for safety monitoring, and were not part of a
controlled clinical trial, were included.
Daptomycin treatment was considered to be
first line when there was no prior use of
antibiotics and second line if prior antibiotics
were used. In this analysis, patients treated with
doses [6 mg/kg/day of daptomycin were
compared with doses B6 mg/kg/day.
Institutional Review Board (IRB) or Ethics
Committee (EC) approval in each country was
obtained before the start of the study and all
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013, and Good Clinical Practices. Informed
consent was obtained according to the
requirements of the IRB or EC and/or local
data privacy regulations.
Effectiveness
Investigators assessed clinical outcomes at the
end of daptomycin therapy according to
protocol-defined criteria: cured (clinical signs
and symptoms resolved, no additional antibiotic
therapywasnecessary, or infection clearedwith a
negative culture reported); improved (partial
resolution of clinical signs and symptoms and/
or additional antibiotic therapy was warranted);
failed (inadequate response to daptomycin
therapy, worsening or new/recurrent signs and
symptoms, need for a change in antibiotic
therapy, or positive culture reported at the end
of therapy); or non-evaluable (unable to
determine response due to insufficient
information) [20]. Clinical success was defined
as cured or improved outcomes.
Safety
Adverse events (AEs) and serious AEs (SAEs)
during daptomycin treatment and the 30-day
follow-up period were assessed by the
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investigators. All reported AEs were recorded,
regardless of their relationship to daptomycin.
Statistical Analysis
Statistical analysis was performed using SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Due to the nature of the trial, inferential
analyses were not conducted and no formal
statistical methodology other than simple
descriptive statistics was used. All analyses
were considered to be explanatory.
Numerical variables are summarized as
arithmetic mean, standard deviation, median,
minimum, first quartile, third quartile, and
maximum for continuous variables.
Categorical variables were summarized by
absolute and relative frequencies.
Simple and multiple post-hoc logistic
regression analyses were performed to
determine whether any factors could have
influenced success rates. These factors included
the dose level, duration of treatment,
bacteremia, comorbidity, use of prior or
concomitant medication, and surgery.
RESULTS
Patient Demographic and Clinical
Characteristics
Of the 6075 patients enrolled in EU-CORE study,
4892 (80.5%) patients received daptomycin
doses B6 mg/kg/day, 1097 (18.1%) patients
received daptomycin doses[6 mg/kg/day, and
dosing information was missing for 86 patients.
Baseline demographics, clinical characteristics,
and significant underlying diseases are
summarized in Table 1. The three dose groups
(B6; [6 to \8; C8 mg/kg/day) were similar in
terms of age, gender, race, and underlying
conditions. Of the 5989 patients with reported
dosing information, 782 (13.1%) had a baseline
creatinine clearance (CrCl) \30 mL/min.
Overall, 542 (9.0%) patients were on dialysis at
initiation of daptomycin therapy and 526 (8.8%)
patients at end of daptomycin therapy. The
proportion of patients with CrCl \30 mL/min
who received daptomycin every 48 h was 44.0%,
while 47.0% received daptomycin every 24 h.
Among patients undergoing continuous renal
replacement therapy (CRRT), 77.2% received
daptomycin every 24 h.
The primary infections with the largest
proportion of patients treated with a high dose
([6 mg/kg/day) were osteomyelitis (37.1%),
foreign body/prosthetic infection (31.6%; mainly
orthopedic, intracardiac and intravascular
devices), and endocarditis (27.6%; Fig. 1).
A trend towards use of higher doses over
time was observed, most notably in the
treatment of osteomyelitis and foreign body/
prosthetic infection (Fig. 2). Median duration of
daptomycin therapy was 10 (range 1–246), 13
(range 1–300), and 14 (range 1–132) days in the
B6, [6 to \8, and C8 mg/kg/day groups,
respectively. The duration of daptomycin
therapy was longer in patients with
osteomyelitis, endocarditis, and foreign body/
prosthetic infection.
Previous and Concomitant Antibiotic
Therapy
Themajority of patients receivedother antibiotic
therapy before daptomycin in the three dose
groups. The most common antibiotics
administered prior to daptomycin were
penicillins and glycopeptides (Table 1).
Treatment failure was the most common reason
for discontinuation of prior antibiotic therapy
(see Appendix 1 in the supplementary material).
Most inpatients received concomitant
antibiotics with daptomycin in the three dose
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groups; those most commonly used for
inpatients included carbapenems, penicillins,
and cephalosporins.
Microbiology
Culture samples were available for 4017
(82.1%), 383 (84.7%) and 577 (89.5%) patients
treated with B6,[6 to\8, and C8 mg/kg/day,
respectively. Approximately, two-thirds of
patients had a positive culture and S. aureus
was the most commonly isolated organism
(Table 2). Patients in high-dose groups had
higher percentage of positive cultures.
Effectiveness
The overall clinical success rate (i.e., cured or
improved) at the end of daptomycin therapy was
82.0% (899/1097) in the high-dose ([6 mg/
Table 1 Demographic and baseline characteristics (safety population)
Characteristic N5 5989
£6 mg/kg/day
(N5 4892), n (%)
>6 to <8 mg/kg/day
(N5 452), n (%)
‡8 mg/kg/day
(N5 645), n (%)
Gender, male 3084 (63.0) 270 (59.7) 382 (59.2)
Age, N
\65 years 2645 (54.1) 250 (55.3) 345 (53.5)
C65 years 2242 (45.8) 202 (44.7) 300 (46.5)
C75 years 1026 (21.0) 94 (20.8) 150 (23.3)
Missing 5 (0.1) 0 (0.0) 0 (0.0)
Race, caucasian 4238 (86.6) 374 (82.7) 544 (84.3)
Renal function
Creatinine clearance\30 mL/min 672 (13.7) 47 (10.4) 63 (9.8)
Patients on dialysis
At initiation of therapy 471 (9.6) 31 (6.9) 40 (6.2)
At end of therapy 452 (9.2) 31 (6.9) 43 (6.7)
Signiﬁcant underlying diseases ([10%)
Cardiovascular 2654 (54.3) 248 (54.9) 375 (58.1)
Diabetes mellitus 1347 (27.5) 108 (23.9) 128 (19.8)
Renal 809 (16.5) 66 (14.6) 76 (11.8)
Oncologic 762 (15.6) 51 (11.3) 101 (15.7)
Pulmonary 646 (13.2) 57 (12.6) 90 (14.0)
Gastrointestinal 602 (12.3) 53 (11.7) 55 (8.5)
Prior antibiotic therapy 3185 (65.1) 306 (67.7) 436 (67.6)
Penicillins 1231 (25.2) 128 (28.3) 173 (26.8)
Glycopeptides 1122 (22.9) 137 (30.3) 198 (30.7)
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kg/day) group and 80.3% (3928/4890) in the
B6 mg/kg/day dose group. The clinical success
rates were consistent for patients with positive
cultures and those with negative cultures or no
culture data. At 30 days, the clinical success rate
was 91.3% (325/356) in the high-dose ([6 mg/
kg/day) group and90.3% (633/701) in theB6 mg/
kg/day dose group. Numerically higher clinical
success rates were observed with increasing dose
for several infections, including endocarditis and
foreign body/prosthetic infection (Table 3).
Clinical outcome was also higher in
coagulase-negative staphylococcal and
enterococcal infections (Fig. 3). The clinical
Fig. 1 Initial daptomycin dose by type of primary infection.
cSSTI complicated skin and soft tissue infection, uSSTI
uncomplicated skin and soft tissue infection. a Septic arthritis,
urinary tract infection/pyelonephritis, necrotizing infections,
necrotizing fasciitis, surgical/non-surgical antibiotic
prophylaxis, neutropenic fever, metastatic abscess, central
nervous system infection, not otherwise speciﬁed
Fig. 2 High-dose daptomycin use over time. cSSTI complicated skin and soft tissue infection
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success rates tended to be greater when
daptomycin was used as first-line therapy [82.1%
(B6 mg/kg), 85.1% ([6 to\8 mg/kg), and 87.9%
(C8 mg/kg)] as compared to second-line therapy
[79.2% (B6 mg/kg), 77.1% ([6 to\8 mg/kg), and
81.9% (C8 mg/kg)].
Results of both simple and multiple logistic
regression analyses were consistent. As shown
in Fig. 4, the clinical success rate was greater in
patients treated with daptomycin doses C8 mg/
kg/day as compared to B6 mg/kg/day, those
who were treated for[28 days as compared to
\14 days, and patients who underwent surgery
as compared to no surgery. All the
corresponding odds ratios were larger than 1.
Safety
AEs, SAEs, and 30-day overall mortality rate
and mortality due to infections are presented
in Table 4. Musculoskeletal and connective
tissue disorders were reported as AEs in 25
(0.4%) patients. A total of 12 cases were
considered by the investigator as related to
daptomycin and among them 5 were SAEs
(Table 4). Rhabdomyolysis and myalgia were
the most reported AEs possibly related to
daptomycin in the B6 mg/kg/day group or
with higher doses of daptomycin but they
were rare (0.2%). Discontinuation of
daptomycin was observed in all patients
Table 2 Primary pathogens in patients with positive cultures (safety population)
Culture result/primary pathogen N5 5989
£6 mg/kg/day
(N5 4892), n (%)
>6 to <8 mg/kg/day
(N5 452), n (%)
‡8 mg/kg/day
(N5 645), n (%)
Culture results available 4017 (82.1) 383 (84.7) 577 (89.5)
Positive culture 3099 (63.3) 304 (67.3) 455 (70.5)
Staphylococcus aureus 1331 (42.9) 129 (42.4) 194 (42.6)
MRSA 733 (55.1) 73 (56.6) 93 (47.9)
MSSA 495 (37.2) 47 (36.4) 93 (47.9)
Methicillin susceptibility unknown 103 (7.7) 9 (7.0) 8 (4.1)
Staphylococcus epidermidis 485 (15.7) 50 (16.4) 101 (22.2)
Other coagulase-negative staphylococci 387 (12.5) 36 (11.8) 47 (10.3)
Enterococcus species
Enterococcus faecalis 182 (5.9) 13 (4.3) 36 (7.9)
Enterococcus faecium 147 (4.7) 16 (5.3) 20 (4.4)
VRE (E. faecalis or E. faecium) 54 (1.7) 2 (0.7) 8 (1.8)
Other Enterococcus spp. 42 (1.4) 3 (1.0) 7 (1.5)
Othera 525 (16.9) 57 (18.8) 50 (11)
MRSA methicillin-resistant S. aureus, MSSA methicillin-susceptible S. aureus, VRE vancomycin-resistant enterococci
a Includes Clostridium perfringens, Clostridium spp., Corynebacterium spp., Streptococcus dysgalactiae, Peptostreptococcus spp.,
Staphylococcus spp. (coagulase not speciﬁed), Streptococcus agalactiae or group B streptococci, Streptococcus dysgalactiae,
Streptococcus dysgalactiae dysgalactiae, Streptococcus dysgalactiae equisimilis, Streptococcus pneumoniae, Streptococcus pyogenes or
group A streptococci, Streptococcus spp., viridans streptococci, Gram-negative bacilli, Gram-negative cocci, Gram-positive
bacilli, Gram-positive cocci, viruses, fungi/yeast, and invalid/ambiguous pathogen code
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with AEs of musculoskeletal and connective
tissue disorders reported as related to
daptomycin.
Rates of AEs leading to daptomycin
discontinuation were similar between dose
groups (4.0, 5.1, and 4.7% in the B6, [6 to
\8, and C8 mg/kg/day groups, respectively).
There were no new or unexpected safety
findings at doses [6 mg/kg/day and no
episodes of eosinophilic pneumonia were
reported.
Increased blood creatine phosphokinase
(CPK) was reported as an AE in 49 (1.0%), 9
(2.0%), and 18 (2.8%) patients in the B6,[6 to
\8, and C8 mg/kg/day groups, respectively
(Table 4). Shift to worsening CrCl from
initiation to end of daptomycin therapy by
daptomycin dose was 10.4% or less for all dose
Table 3 Positive blood culture and clinical success rates by primary infection (efﬁcacy population)
Primary
infection



















cSSTI 125/1689 (7.4) 102/125 (81.6) 7/117 (6.0) 4/7 (57.1) 12/100 (12.0) 10/12 (83.3)
Bacteremiaa 690/1041 (66.3) 531/690 (77.0) 53/82 (64.6) 38/53 (71.7) 89/120 (74.2) 68/89 (76.4)




114/403 (28.3) 83/114 (72.8) 15/60 (25.0) 13/15 (86.7) 43/126 (34.1) 39/43 (90.7)
Osteomyelitis 17/263 (6.5) 13/17 (76.5) 10/71 (14.1) 6/10 (60.0) 16/84 (19.0) 11/16 (68.8)
cSSTI complicated skin and soft tissue infection
a Results of blood cultures may not have been reported for all patients
Fig. 3 Clinical success by primary pathogen and dose. CoNS coagulase-negative staphylococci, MRSA methicillin-resistant
S. aureus, MSSA methicillin-susceptible S. aureus
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ranges [B6 mg/kg/day (8.2%), [6 and \8 mg/
kg/day (10.4%), C8 mg/kg/day (9.5%)].
A total of 782 (13.1%) patients had a baseline
CrCl \30 mL/min. Overall AEs or SAEs were
reported at greater frequencies in patients with
CrCl \30 mL/min who received daptomycin
every 24 h as compared with the total patient
population (Table 4). There were no safety
signals associated with daptomycin therapy in
these patients.
DISCUSSION
High-dose daptomycin treatment has been
recommended for difficult-to-treat
Gram-positive infections within various
national and international guidelines [6,
10–12]. Although higher doses of daptomycin
are increasingly prescribed for severe infections
[21], there are a few studies evaluating the
effectiveness of high dose. Patients within
EU-CORE were more likely to be treated with
high-dose daptomycin, if they had bacteremia,
endocarditis, osteomyelitis, or foreign body/
prosthetic infection. Numerically higher
clinical success rate was observed with
increasing dose in endocarditis and foreign
body/prosthetic infection. As previously
observed, success rates were higher when
daptomycin was used as first-line treatment
and this difference was observed across all
dosing groups [22]. Logistic regression analyses
revealed that factors contributing to statistically
significant higher success rates were dose level
(C8 mg/kg/day), treatment duration ([28 days),
and surgery. The higher success rate in patients
treated for[28 days could be explained by the
management of serious infections (e.g.,
Fig. 4 Logistic regression analysis of clinical success versus failure or non-evaluable. Data are presented as odds ratio and 95%
conﬁdence interval. An odds ratio[1 favors the former category and an odds ratio\1 favors the latter category
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osteomyelitis, endocarditis, and foreign body/
prosthetic infection) that typically require a
prolonged course of antibiotic therapy.
Effectiveness and safety of high-dose
daptomycin treatment has been observed in
several difficult-to-treat infections including
Table 4 Safety in patients receiving daptomycin by dose group (safety population)
Safety parameter £6 mg/kg/day
(N5 4892)a, n (%)
>6 to <8 mg/kg/day
(N5 452)a, n (%)
‡8 mg/kg/day
(N5 645)a, n (%)
Deathb 329 (6.7) 40 (8.8) 29 (4.5)
30-day mortality 272 (5.6) 33 (7.3) 26 (4.0)
30-day mortality due to infections 138 (2.8) 16 (3.5) 17 (2.6)
Any SAE 448 (9.2) 62 (13.7) 57 (8.8)
Patients with CrCl\30 mL/min dosed every
24 h, n/N (%)
55/301 (18.3) 8/27 (29.6) 8/33 (24.2)
Any AE 650 (13.3) 94 (20.8) 107 (16.6)
Patients with CrCl\30 mL/min dosed every
24 h, n/N (%)
64/301 (21.3) 9/27 (33.3) 8/33 (24.2)
Any AE by treatment durationc
1–14 days, n/N (%) 440/3238 (13.6) 56/252 (22.2) 57/324 (17.6)
15–28 days, n/N (%) 136/1072 (12.7) 23/112 (20.5) 31/173 (17.9)
[28 days, n/N (%) 72/515 (14.0) 15/82 (18.3) 19/140 (13.6)
SAEs possibly related to daptomycin 29 (0.6) 9 (2.0) 10 (1.6)
AEs possibly related to daptomycin 126 (2.6) 24 (5.3) 42 (6.5)
Patients with AE leading to study drug
discontinuation
195 (4.0) 23 (5.1) 30 (4.7)
AE of blood creatine phosphokinase increased 49 (1.0) 9 (2.0) 18 (2.8)
Musculoskeletal and connective tissue disorders
(AEs related to daptomycin)
8 (0.2) 2 (0.4) 2 (0.3)
Rhabdomyolysis 4 (0.1)d 0 (0.0) 1 (0.2)d
Myositis 0 (0.0) 1 (0.2)d 0 (0.0)
Myalgia 3 (0.1) 0 (0.0) 1 (0.2)
Myopathy 0 (0.0) 1 (0.2) 0 (0.0)
Muscular weakness 1 (0.0) 0 (0.0) 0 (0.0)
AE adverse event, CrCl creatinine clearance, SAE serious AE
a Unless otherwise indicated
b Excluding follow-up period
c Treatment duration may not have been reported for all patients
d All considered as SAE except one case in the B6 mg/kg/day group
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mediastinitis after cardiac surgery and
osteomyelitis [23, 24]. A retrospective
evaluation of the effectiveness and safety of
high-dose daptomycin therapy ([6 mg/kg/day)
in a multicenter cohort of 245 adult patients
with enterococcal infections showed that
high-dose daptomycin was effective and safe
[9]. Furthermore, high-dose daptomycin was
shown to be an effective and safe alternative to
standard-of-care in the treatment of left-sided
endocarditis due to common Gram-positive
pathogens [15, 16]. The clinical success rates
observed in the present study for endocarditis
are consistent with results from these prior
studies where numerically higher clinical
success rates were observed with daptomycin
doses of at least 8 mg/kg/day.
Daptomycin exhibits
concentration-dependent activity [3] and
higher doses of daptomycin are associated
with increased degree and speed of bactericidal
activity [25]. Furthermore, since Enterococcus
species usually have higher minimum
inhibitory concentrations (MICs) of
daptomycin than other Gram-positive
pathogens, patients with enterococcal
infections may require higher doses of
daptomycin. Increasing prevalence and
recognition of reduced susceptibility to
glycopeptides amongst staphylococcal species
is another reason why high-dose daptomycin
can be a therapeutic option of interest. Others
have argued that in view of the variability in
pharmacokinetic parameters, MIC distribution
and pharmacodynamics of important bacterial
populations, high-dose daptomycin (10 mg/
kg/day) could enhance clinical outcomes in
complex infections [26]. In a retrospective
cohort case–control analysis, clinical outcomes
of patients treated with either daptomycin
(8–10 mg/kg/day) or vancomycin for MRSA
bacteremia with vancomycin MIC values
C1.5 mg/L were compared [17]. The
daptomycin group had a favorable outcome at
14 and 30 days. In agreement with this study,
our results confirm that daptomycin doses
[6 mg/kg/day with a median duration of
approximately 14 days was effective in the
treatment of patients with infections including
endocarditis, bacteremia, skin and soft tissue
infection, foreign body/prosthetic infection,
and osteomyelitis. In patients with renal
impairment (CrCl\30 mL/min), the
recommended dosing interval for daptomycin
is every 48 h. Unlike in patients undergoing
hemodialysis or continuous ambulatory
peritoneal dialysis, the pharmacokinetics of
daptomycin in patients receiving CRRT are
similar to healthy volunteers. Therefore,
dosing frequency in these patients should be
every 24 h [27, 28], as reported in this registry
where daptomycin was given every 24 h in
77.8% of patients on CRRT.
This study showed that daptomycin at doses
[6 mg/kg/day was well tolerated with no new or
unexpected safety findings. CPK elevation is a
well-known safety signal for daptomycin, and
baseline and weekly CPK measurement is
recommended during high-dose daptomycin
therapy. A few studies have reported CPK
elevations that led to drug discontinuation due
to musculoskeletal symptoms or related AEs [13,
14, 25], while others have reported high-dose
daptomycin to be safe with no elevations of CPK
[29, 30]. Fowler et al. [31] observed CPK
elevations of 6.7% for daptomycin (6 mg/kg
every 24 h) versus 0.9% for the comparator
group in the complex S. aureus bacteremia and
endocarditis study. In contrast, CPK elevations
observed in the current study in patients treated
with high-dose daptomycin were lower (2.0%
and 3.0% in the [6 to \8 and C8 mg/kg/day
groups, respectively). Muscular events were rare
and seemed tobe similar in the threedose groups.
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The limitations of this study include the
inherent limitations that are expected in
real-world observational studies, which include
non-randomized trial design, non-blinded
interpretation of results, and the subjective
assessments of clinical outcomes as
determined by individual investigators.
CONCLUSION
High-dose daptomycin ([6 mg/kg/day)
exhibited good safety and tolerability profile.
These findings, combined with high success
rates in a large spectrum of infections and
against a wide range of pathogens, suggest
that high-dose daptomycin ([6 mg/kg/day) is a
therapeutic option in patients with
difficult-to-treat infections and may provide
better outcome for some infections.
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